These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38268449)

  • 21. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 22. Survival adjusting for crossover: phase 3 study of ibrutinib
    Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
    Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
    [No Abstract]   [Full Text] [Related]  

  • 23. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
    Woyach JA
    Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
    [No Abstract]   [Full Text] [Related]  

  • 25. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
    Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA
    Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
    Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
    J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
    Bond DA; Maddocks KJ
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
    Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
    Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Ibrutinib Therapy Reverses CD8
    Parry HM; Mirajkar N; Cutmore N; Zuo J; Long H; Kwok M; Oldrieve C; Hudson C; Stankovic T; Paneesha S; Kelly M; Begum J; McSkeane T; Pratt G; Moss P
    Front Immunol; 2019; 10():2832. PubMed ID: 31921116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
    Gordon MJ; Sitlinger A; Salous T; Alqahtani H; Churnetski M; Rivera X; Wisniewski P; Cohen J; Patel K; Shadman M; Choi M; Hill B; Stephens D; Persky D; Brander D; Danilov AV
    Leuk Res; 2020 Feb; 89():106302. PubMed ID: 31982152
    [No Abstract]   [Full Text] [Related]  

  • 33. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
    Ahn IE; Farooqui MZH; Tian X; Valdez J; Sun C; Soto S; Lotter J; Housel S; Stetler-Stevenson M; Yuan CM; Maric I; Calvo KR; Nierman P; Hughes TE; Saba NS; Marti GE; Pittaluga S; Herman SEM; Niemann CU; Pedersen LB; Geisler CH; Childs R; Aue G; Wiestner A
    Blood; 2018 May; 131(21):2357-2366. PubMed ID: 29483101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
    Patel VK; Lamothe B; Ayres ML; Gay J; Cheung JP; Balakrishnan K; Ivan C; Morse J; Nelson M; Keating MJ; Wierda WG; Marszalek JR; Gandhi V
    Leukemia; 2018 Apr; 32(4):920-930. PubMed ID: 29099493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
    Khan Y; O'Brien S
    Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real-world study based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Zhao ZX; Yang TY; Wang YH; Zhang L; Li J; Su YW
    Br J Clin Pharmacol; 2024 Sep; 90(9):2166-2179. PubMed ID: 38831641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
    Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ
    Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Javidi-Sharifi N; Brown JR
    Expert Rev Hematol; 2024 Jun; 17(6):201-210. PubMed ID: 38784995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
    Tobinai K; Uchida T; Fukuhara N; Nishikawa T
    Int J Hematol; 2019 Mar; 109(3):366-368. PubMed ID: 30623356
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
    Kipps TJ; Fraser G; Coutre SE; Brown JR; Barrientos JC; Barr PM; Byrd JC; O'Brien SM; Dilhuydy MS; Hillmen P; Jaeger U; Moreno C; Cramer P; Stilgenbauer S; Chanan-Khan AA; Mahler M; Salman M; Eckert K; Solman IG; Balasubramanian S; Cheng M; Londhe A; Ninomoto J; Howes A; James DF; Hallek M
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):715-722.e6. PubMed ID: 31447270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.